Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gefitinib
Drug ID BADD_D01008
Description Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Indications and Usage For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.
Marketing Status Prescription; Discontinued
ATC Code L01EB01
DrugBank ID DB00317
KEGG ID D01977
MeSH ID D000077156
PubChem ID 123631
TTD Drug ID D09XZB
NDC Product Code 54245-1359; 65344-0029; 54893-0036; 63850-8070; 53104-7700; 73377-128; 0310-0482; 61200-002; 46708-880; 68554-0060
Synonyms Gefitinib | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | Iressa | ZD1839 | ZD 1839
Chemical Information
Molecular Formula C22H24ClFN4O3
CAS Registry Number 184475-35-2
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oropharyngeal pain22.02.05.022; 07.05.05.004--
Acute kidney injury20.01.03.016--
Ocular ischaemic syndrome24.04.09.005; 06.07.02.005--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.002131%Not Available
Sinus node dysfunction02.03.03.017--
Multiple organ dysfunction syndrome08.01.03.0570.000278%
Liver function test increased13.03.01.0440.000533%Not Available
Carcinoembryonic antigen increased13.22.01.0090.000533%Not Available
Lung carcinoma cell type unspecified recurrent22.08.01.018; 16.19.02.0050.000208%Not Available
Malignant pleural effusion16.32.03.014; 22.05.04.0010.000208%Not Available
Metastases to adrenals16.22.02.012; 05.01.04.0070.000799%Not Available
Metastases to bone16.22.02.005; 15.09.03.0060.001598%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000208%Not Available
Metastases to pleura16.22.02.022; 22.05.04.0020.000278%Not Available
Metastases to the mediastinum22.09.03.009; 16.22.02.0270.000533%Not Available
Tumour marker increased13.22.01.0170.000533%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000764%Not Available
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000208%Not Available
Acquired gene mutation08.01.10.0020.005062%Not Available
Infectious pleural effusion22.05.01.004; 11.01.09.0110.000533%Not Available
EGFR gene mutation08.01.10.0040.000417%Not Available
Cutaneous symptom23.07.04.0230.000533%Not Available
The 10th Page    First    Pre   10    Total 10 Pages